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Summary. Modern analysis of incomplete longitudinal outcomes involves formulating
assumptions about the missingness mechanisms and then using a statistical method that
produces valid inferences under this assumption. In this manuscript, we deﬁne missingness
strategies for analyzing randomized clinical trials (RCTs) based on plausible clinical sce-
narios. Penalties for drop-out are also introduced in an attempt to balance beneﬁts against
risks. Some missingness mechanisms are assumed to be non-future dependent (NFD) which
is a subclass of missing-not-at-random. NFD stipulates that missingness depends on the
past and the present information, but not on the future. Missingness strategies are im-
plemented in the pattern-mixture modeling (PMM) framework using multiple imputation
(MI) and it is shown how to estimate the marginal treatment eﬀect. Next, we outline how
MI can be used to investigate the impact of drop-out strategies in subgroups of interest.
Finally, we provide the reader with some points to consider when implementing PMM-MI
analyses in conﬁrmatory RCTs. The data set that motivated our investigation comes from
a placebo-controlled RCT design to assess the eﬀect on pain of a new compound.
KEY WORDS : incomplete longitudinal outcome ; missing not at random ; non-future
dependence ; pattern-mixture model ; multiple imputation.
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1 Introduction
Clinical developers are becoming increasingly aware of good practices in analyzing in-
complete longitudinal outcomes in randomized clinical trials (RCTs). Their analyses involve
formulating assumptions about the missingness mechanisms and then using a statistical
method that produces valid inferences under these assumptions. Consequently, the formu-
lation of missingness assumptions in a transparent and interpretable manner has become
a key aspect. A major cause of missingness in RCTs is drop-out. Missingness is at random
(MAR) if drop-out occurrence is independent of missing outcome values, conditionally on
the observed ones. If the covariates are fully observed, additional dependence on covariates
is allowed for too. When MAR fails to hold, missingness is not at random (MNAR). MNAR
implies that drop-out occurrence depends on an outside variable not in the model or is re-
lated to unobserved outcome values at the drop-out time and possibly afterwards, even
when conditioned on available information. The consequence of MNAR is that missing
outcome values cannot be reliably predicted using observed measurements (i.e., covariates
and outcome values).
Pattern-mixture modeling (PMM) is a framework that can be considered when mis-
singness is MNAR [1]. PMM stratiﬁes the sample of subjects by missingness pattern and
formulates distinct models to estimate parameters within each pattern. In RCTs with mul-
tiple scheduled visits, time is often modeled as a ﬁxed class eﬀect and patterns are deﬁned
based on drop-out at every visit. Whereas parameters are all identiﬁed in completers (i.e.,
subjects who complete the trial until the last visit), some parameters are unidentiﬁed in
the patterns of drop-out subjects. This can be overcome by setting unidentiﬁed parameters
equal to functions of the parameters describing the distributions of other patterns.
The so-called identifying restrictions indicate from which patterns information is borro-
wed. In Little's taxonomy [2], complete-case missing values (CCMV) stipulates that missing
information is borrowed from completers. In neighboring-case missing values (NCMV), the
closest neighboring pattern is used instead. NCMV implies that any unidentiﬁed parameter
at a visit is estimated in the pattern of subjects having their last observed outcome value
at this visit. Available-case missing values (ACMV) oﬀers a compromise between CCMV
and NCMV as all available patterns are used weighted by occurrence of each pattern.
ACMV has a particular status since this is the natural counterpart of MAR in the PMM
framework. In practice, analysis assuming MAR is often a point of departure for sensitivity
analyses assuming MNAR.
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Non-future missing values (NFMV) is another identifying restriction that oﬀers ap-
pealing perspectives for sensitivity analysis since the user has full freedom to choose the
distribution of the ﬁrst unobserved (or present) outcome value given previous measure-
ments. Under NFMV, missingness depends on the past and the present, but not on future
unobserved outcome values. In other words, missingness is non-future dependent (NFD).
NFD assumption is a sub-class of MNAR. The correspondence between NFMV and NFD
allows the formulation of comprehensible drop-out strategies since drop-out mechanisms
are directly characterized by the free distributions of present outcome values.
In this manuscript, we deﬁne several drop-out strategies based on plausible clinical sce-
narios. We suggest solutions to overcome major drawbacks of well known single-imputation
concepts such as baseline-observation-carried-forward (BOCF) and last-observation-carried-
forward (LOCF). In an attempt to balance beneﬁts against risks in the assessment of the
treatment eﬀect, we introduce penalties which are intended to reﬂect the prejudice suﬀered
by subjects due to drop-out. In the last set of drop-out strategies, we question the choice
of the ﬁrst unobserved visit to characterize the present in our NFD implementation.
Drop-out strategies are implemented in the pattern-mixture modeling (PMM) frame-
work using multiple imputation (MI). We propose an approach to analyse the marginal
treatment eﬀect in the presence of moderate imbalance in the treatment allocations across
patterns. MI-based methods oﬀer a transparent way to represent missingness strategies [3].
In line with this, we investigate the impact of drop-out strategies in subgroups of interest
using individual proﬁles obtained from the imputed values. Finally, we provide technical
information to implement analysis using an existing freely-available SAS program [4].
To this end, we have re-analyzed a data set that comes from a placebo-controlled clinical
trial to assess the eﬀect on pain of a new compound [5][6]. A continuous visual analogue
scale (VAS) was used to assess pain intensity and a binary outcome, whose values indicate
clinical response or non-response, was derived. The next section describes the case study
and outlines some points to consider during analysis preparation. Identifying restrictions
and drop-out strategies are laid out in Section 3. In Section 4, we describe our approach
to analyse the marginal treatment eﬀect. Results obtained under drop-out strategies are
contrasted in Section 5 whereas Section 6 and 7, respectively, contain the discussion and
the concluding remarks. The appendix provides the information to implement analysis
using software.
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2 Case study
2.1 Trial design and statistical objectives
The data set was collected in a multi-country European phase-III double-blind clinical
trial of which the objective was to compare the eﬀect on pain intensity of a test product
(Test) versus placebo (PCB) in subjects suﬀering from ﬁbromyalgia. Four hundred thirty
three (433) subjects were randomized to receive Test versus 447 subjects to receive PCB,
that is 880 subjects in total.
After random assignment to either Test or PCB at the randomization visit (visit 0),
subjects underwent a four-week escalation dose period followed by three four-week periods
under stable dose. All periods ended at the scheduled monthly visits that are visit 1 at the
end of dose escalation and visits 24 under stable dose. Subjects who discontinued were
asked to undergo a speciﬁc visit at the discontinuation date, termed the drop-out visit.
Pain intensity was reported by subjects on a VAS that ranges from 0 (no pain) to 100
(worst pain imaginable) on a daily basis using an electronic diary. To obtain pain intensity
levels by visit, these daily assessments were averaged over 2-week periods prior to the visits.
The two-week period oﬀers a reasonable compromise between one week which covers too
short a period to be clinically meaningful and 4 weeks, which presents the disadvantage
that, as pain intensity is recorded daily between a target visit and the preceding one, the
assessments in the ﬁrst two weeks are more related to the preceding visit than to the target
visit. Last, the four values of a continuous longitudinal outcome were derived as the pain
intensity level at randomisation minus the ones at visits 14. Thus, a positive value of
outcome indicates a decrease in pain intensity.
The statistical properties of outcome were studied with respect to the averaging period
length in [5]. It is especially mentioned that the mean and the variability of outcome values
decrease as the averaging period length increases. The decrease of mean is caused by the
global trend in the pain intensity to improve over time. So, any extension of the averaging
period toward the preceding visit tends to involve worse pain assessments.
Next, the four values of a longitudinal binary outcome were derived in terms of clinical
response based on a minimum 30% improvement of the pain level at randomisation on
the continuous outcome values. In chronic pain diseases, including ﬁbromyalgia, this gain
is regarded as clinically relevant. For the drop-out subjects, the pain intensity level was
assessed at the drop-out visit, and the corresponding values of the continuous and the
binary outcomes were repositioned to the next scheduled visit for analysis.
4
The estimation of treatment eﬀect at visit 4 was the primary objective of the trial.
The original analyses, as mentioned in the trial protocol, were based on BOCF and LOCF
principles to impute missing outcome values. The continuous outcome values were ﬁtted
using a covariance analysis model and the binary outcome values were ﬁtted using a logistic
regression model. Pain level at randomization was a pre-speciﬁed key covariate whereas
country was a pre-speciﬁed stratum factor. The objective of the analyses described in this
manuscript is to assess the treatment eﬀects at visit 4 adjusted on the same covariate and
stratum factor under a set of drop-out strategies. Analyses are conducted on all randomized
subjects.
2.2 Causes of missingness
Out of the 880 randomized subjects, 77/447 subjects (17.2%) in the PCB group and
126/433 subjects (29.1%) in the Test group dropped out from the trial. In our case study,
drop-out from the trial also means drop-out from the follow-up even if treatment intake
had stopped earlier. Three subjects who dropped out very early have no assessment after
randomization. All the other drop-out subjects have completed their drop-out visit and
reported their pain intensity level. There are only two `intermittent' missing pain levels
(i.e., pain levels missing not due to drop-out). The ﬁrst occurred at the randomization visit
because of a technical problem with the electronic diary whereas the second occurred at
visit 3 and was caused by the absence of a subject from home.
The distribution of subjects by drop-out cause by treatment group is given in Table 1.
Table 1  Frequencies (percentages) of subjects by drop-out cause by treatment group
Causes PCB Test
Adverse event (AE) 44 (9.8) 96 (22.2)
Serious AE due to treat. 1 (0.2) 3 (0.7)
AE due to treatment 30 (6.7) 89 (20.6)
Serious AE not due to treat. 3 (0.7) 0 (_)
AE not due to treatment 10 (2.2) 4 (0.9)
Other than AE 33 (7.4) 30 (7.0)
Patients's decision 11 (2.5) 11 (2.5)
Investigator's decision 0 4 (0.9)
Therapeutic failure 18 (4.0) 10 (2.3)
Other reasons 4 (0.9) 5 (1.2)
Total 77 (17.2) 126 (29.1)
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The main cause of drop-out was adverse event (AE). The higher drop-out rate for Test
stems from a higher occurrence of AEs in this group. Particularly, there are three times
more subjects who dropped out for AE due to the treatment in the Test group than in the
PCB group (6.7% for PCB versus 20.6% for Test). Among the 119 concerned AEs, most of
them were pre-identiﬁed and particularly under investigation. These can be gathered into
four classes :
. Cardio-vascular disorders including tachycardia, hypertension, and heart rate in-
crease with 2/447 (0.4%) for PCB versus 25/430 (5.8%) for Test,
. Gastrointestinal disorders including nausea and vomiting with 4/447 (0.9%) for
PCB versus 12/430 (2.8%) for Test,
. Skin reactions including rash and hyperhydrosis with 1/447 (0.2%) for PCB versus
15/430 (3.5%) for Test,
. Nervous system disorders including dizziness and headache with 6/447 (1.3%) for
PCB versus 15/430 (3.5%) for Test.
Conversely, subjects who dropped out for other causes than AE are similarly distributed
in the two groups with 7.4% for PCB and 7.0% for Test. In this category, therapeutic
failure concerns twice less subjects under Test (2.3%) than under PCB (4.0%). Further
investigations (not shown in Table 1) reveal that the earlier the drop-out, the greater the
rate of drop-out caused by AE (from 77.8% if drop-out occurs between randomization and
visit 1 to 40.6% between visit 3 and visit 4). The distribution of drop-out causes in our
case study is classical of many clinical trials in chronic pain.
2.3 Characteristics of patterns
Patterns are deﬁned based on drop-out at every visit. Accordingly, patterns 04 res-
pectively consist of subjects with 0 to 4 available outcome values. Pattern 0 contains the
subjects without pain level at randomisation and the three subjects without pain level after
randomization. Pattern 4 contains the subjects with complete outcome proﬁle. However,
this pattern does not allow distinguishing between the completers and the subjects who
dropped out after visit 3 and have their drop-out visit repositioned to visit 4. To clarify
this, we deﬁne a pattern 5 which contains the completers, whereas pattern 4 keeps the
subjects who dropped out after visit 3. This separation does not contradict the pattern
deﬁnition given hereabove since one may consider that the completers actually dropped
out at a virtual visit 5 after the end of the trial follow-up.
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Figure 1 displays the unadjusted mean proﬁles per pattern by treatment group.
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Figure 1  Unadjusted mean proﬁles and frequencies per pattern by treatment group.
We ﬁrst observe a substantial diﬀerence between treatment groups in the means per pat-
tern at visit 1. This is caused by the early response to the treatment during the escalation
dose period (from randomization to visit 1) which is larger under Test than under PCB.
In subjects who stay longer on the trial, the mean proﬁles of drop-out patterns exhibit a
stagnation until the drop-out visit.
Conversely, the pattern of completers (pattern 5) shows sustained improvement until
visit 4 in the two treatment groups. It is worthwhile noting that the mean proﬁles in
patterns 4 exhibit a huge diﬀerence between treatment groups. This diﬀerence is partly
explained by the causes of drop-out, which are less related to AE and probably more to
eﬃcacy, in this drop-out pattern than in the others. The diﬀerence in the mean proﬁles
between pattern 4 and pattern 5 supports the decision of separating them.
2.4 Pattern sizes by stratum
Pattern sizes by stratum is an important point to consider before implementing a strati-
ﬁed PMM analysis. The reason is that parameter estimation can fail if a minimum number
of values are not available. In our case study, pattern 0 is not used for parameter estimation
but is pooled with pattern 1 for imputation. The imputation models are fully described in
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Section 4.1. Particularly, the stratum factor country and the full group-by-visit interaction
are speciﬁed as ﬁxed factors. In this setting, parameter estimation requires a minimum of
three available outcome values per pattern by country by treatment group. As the trial
was conducted in twelve European countries, this pre-requisite is not reached and a tricky
pooling of countries must be done.
The trial was conducted in the Czech republic (CZ ; n =55), Denmark (DK ; n =17),
Finland (FI ; n =60), France (FR ; n =184), Germany (GE ; n =42), Italy (IT ; n =101),
Norway (NO ; n =53), Poland (PL ; n =31), Portugal (PT ; n =16), Romania (RO ; n =59),
Spain (ES ; n =111), and Sweden (SE ; n =151). A ﬁrst pooling of countries into four
regions was done based on their geographical proximity. These regions are central Europe
(CZ, GE, PL, RO), southern Europe (ES, IT, PT), France (FR), and the Nordic countries
(DK, FI, NO, SE). Then, central and southern Europe were pooled into the same region
to reach the minimum pattern size. The consequence of this pooling is that the stratum
factor country is replaced by the three-class factor `region' in the imputation models.
The pattern sizes by region by treatment group are provided in Table 2.
Table 2  Pattern sizes by region by treatment group
central + south France nordic countries All Countries
Patterns 0+1 PCB 1+11 9 1+9 2+29
Test 1+28 10 1+23 2+61
Pattern 2 PCB 9 4 8 21
Test 11 5 11 27
Pattern 3 PCB 4 4 4 12
Test 3 7 7 17
Pattern 4 PCB 4 3 6 13
Test 11 3 5 19
Pattern 5 PCB 187 70 113 370
Test 145 69 93 307
All Patterns PCB 216 90 141 447
Test 199 94 140 433
All Groups 415 184 281 880
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3 Identifying restrictions and drop-out strategies
3.1 Description of identifying restrictions
The basis of pattern-mixture modeling results from a particular decomposition of the
joint distribution of the outcome variable together with the drop-out indicator. The pattern-
mixture distribution of the complete outcome values y1, . . . , yT is given by :
f(y1, . . . , yT ) =
T∑
t=1
αtft(y1, . . . , yT ), (1)
where αt denotes the probability of pattern t and ft(y1, . . . , yT ) stands for f(y1, . . . , yT |t).
In our case study, patterns are deﬁned based on drop-out at every visit. More precisely,
if the tth outcome value is the last observed one in a subject, this subject belongs to pattern
t, t = 1, . . . , T . In (1), the distribution of the whole population is expressed in terms of a
mixture of the distributions of pattern populations. These, in turn can be decomposed as :
ft(y1, . . . , yT ) = ft(y1, . . . , yt)ft(yt+1, . . . , yT |y1, . . . , yt)
= ft(y1, . . . , yt)
T∏
s=t+1
ft(ys|y1, . . . , ys−1). (2)
The ﬁrst component in (2) is identiﬁed from the observed outcome values. The second is a
product of conditional pattern distributions, which are unidentiﬁed since the values of ys
are unobserved in these patterns. This can be overcome by setting unidentiﬁed parameters
equal to functions of the parameters describing the distributions of other patterns. The
identifying restrictions, informally introduced in Section 1, are used to this eﬀect.
Under CCMV, identiﬁcation is based on pattern T , the pattern of completers. This can
be formalized by :
ft(ys|y1, . . . , ys−1) = fT (ys|y1, . . . , ys−1), s = t+ 1, . . . , T. (3)
Under NCMV, the neighboring pattern is used instead :
ft(ys|y1, . . . , ys−1) = fs(ys|y1, . . . , ys−1), s = t+ 1, . . . , T. (4)
Identiﬁcation can also be based on all identiﬁed patterns as speciﬁed in the formulation :
ft(ys|y1, . . . , ys−1) =
T∑
j=s
ωsjfj(ys|y1, . . . , ys−1), s = t+ 1, . . . , T. (5)
Every convex set of ωsj 's that sums to 1 provides a valid identiﬁcation scheme. In [8], the
ωsj 's are determined such that (5) corresponds with ACMV.
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Alternatively, NFMV oﬀers the appealing characteristic that the distributions of present
values, that we denote by gt for the sake of clarity, are left unconstrained [9]. In our analysis,
we set the gt's equal to their ft+1 counterparts, in the spirit of NCMV, with a possibility
to shift the mean by a value ∆. Formally, this can be expressed by :
gt(yt+1|y1, . . . , yt) = ft+1(yt+1+∆|y1, . . . , yt). (6)
Future values are then imputed, under ACMV, conditionally on the past and the present.
In our case study, the closest neighboring patterns involved in NCMV and NFMV are
all drop-out patterns. Indeed, pattern 5 is never used for identiﬁcation since pattern 4
does not contain incomplete outcome proﬁles. Of note, the alternative choice of basing
NFMV identiﬁcation on the pattern of completers, in the spirit of CCMV, would have
been inappropriately optimistic. As described in Figure 1, the mean proﬁles of completers
show regular improvements in the two treatment groups, whereas the mean proﬁles of the
drop-out patterns exhibit stagnation over time. Moreover, the large size of patterns 5 would
impose an inappropriately low uncertainty for parameter estimation.
The correspondence between NFMV and NFD allows formally relating drop-out occur-
rence to the gt's. Through (6), we state that drop-out is caused by, or associated with, a
mean decrease by 4 of the present values relative to the values observed in subjects who
dropped out at this visit, without other possible causes, or associations, involving future
values.
3.2 Description of drop-out strategies
Although MAR is impossible to demonstrate [10], primary analysis in RCTs often relies
on this assumption. As laid out in [7], MAR is compatible with de jure (or per-protocol)
analysis of which an objective is to estimate the treatment eﬀect as if a drop-out subject
continued the trial under the same conditions until the last scheduled visit. A consequence
in our case study is that the imputation parameters are estimated using all subjects in
the two treatment groups. This rule is applied under ACMV, which is the counterpart of
MAR, as well as under CCMV and NCMV, which are often used to study the eﬀect of a
certain departure from MAR. These three identifying restrictions characterize the de jure
analyses.
Alternatively, a de facto (or intention-to-treat) analysis aims to reﬂect the eﬀect of the
treatment as well as the impact of treatment withdrawal subsequent to drop-out. In our case
study, we assume that subjects under PCB continue on PCB after drop-out and subjects
10
under Test switch to PCB. Consequently, the imputation parameters are estimated using
subjects of the PCB group only. This approach is referred to as jump to reference (J2R)
in earlier work [17].
De facto analyses are characterized by drop-out strategies based on NFD. We ﬁrst intro-
duce N-LOCF which is intended to overcome a major drawback of LOCF single imputation
by allowing an appropriate degree of uncertainty. Under N-LOCF, the present values are
imputed without shifting subjects' distribution mean (i.e., 4 = 0). So, we expect that a
drop-out subject behaves as a subject of the neighboring pattern in the PCB group with
the same previous measurements. Future values are then imputed conditionally on the past
and the present, assuming PCB-MAR. In the same vein, we deﬁne N-BOCF which takes
up the concept of BOCF single imputation. Under N-BOCF, we set the values of 4 equal
to minus the individual gains observed from randomization to the drop-out visit.
The following drop-out strategies rely on clinical rationales. In an attempt to balance
beneﬁts against risks in the assessment of the treatment eﬀect, we now introduce penalties
which are supposed to reﬂect the prejudice suﬀered by subjects due to drop-out. Under N-
DO5, any drop-out is associated with a penalty set to4=−5. This value was discussed and
approved for its clinical meaningfulness by experts in chronic pain. This also corresponds
to minus the expected treatment eﬀect under the alternative in the trial protocol.
The drop-out strategy N-AE5 reﬁnes N-DO5 by incorporating information about the
cause of drop-out. Under N-AE5, missing outcome values are imputed, assuming :
1. NFD(4=−5) if a subject drops out for AE due to the treatment,
2. NFD(4=−10) if a subject drops out for serious AE due to the treatment,
3. N-LOCF or NFD(4 = 0) if a subject drops out for AE not due to the treatment,
4. MAR if a subject drops out for other reasons than AE.
Since the drop-out rate is greater in the Test group, the greater the penalty, the greater
the conservatism introduced by NFD into the analysis. The next two drop-out strategies
aim at measuring the impact of penalty increase. If subjects dropped out for AE due to the
treatment, the penalty value is brought to 4 = −10 in N-AE10 and 4 = −15 in N-AE15.
The other rules in N-AE5, i.e., the doubling of the ∆ value if AE is serious and the zeroing
if AE is not due to the treatment, are kept in N-AE10 and N-AE15.
In the last set of drop-out strategies, we question the choice of the ﬁrst unobserved visit
to characterize the present in our NFD implementation. Indeed, the drop-out visits are
repositioned to the next scheduled visit for analysis. So, in many drop-out subjects the ﬁrst
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unobserved visits may be likened to a (near) future. Moreover, the inﬂuence of the cause
of drop-out, such as an AE, on a subject's assessment is not well characterized. Thereby,
we cannot rule out that the outcome value at a drop-out visit combines some aspects
of eﬃcacy and safety. In an attempt to address this, we introduce N-AE5-L, N-AE10-L,
and N-AE15-L, which copy the penalty rules applied in N-AE5, N-AE10, and N-AE15,
respectively. However, the drop-out visits are removed from analysis in the subjects who
dropped out for AE.
In Section 5, we compare the results obtained from the de jure and de facto analyses
to those obtained after BOCF and LOCF single imputations, as well as in completers and
in subjects with complete outcome proﬁles (i.e., in subjects who dropped out after visit
3). All analyses are conducted using the same statistical models, which are described in
the next section. For BOCF and LOCF analyses speciﬁcally, the three subjects of pattern
0 without pain level after randomization are imputed with a 0 value for the continuous
outcome and a clinical non-response. The fourth subject of pattern 0 without pain level at
randomization is excluded from analyses.
Table 3 sums up the drop-out strategies described in this section.
Table 3  Description of drop-out strategies
Type of Drop-out Missingness Type of Parameter Data set
analysis strategy mechanisms imputation estimation
_ BOCF Unknown Single _ All visits
_ LOCF Unknown Single _ All visits
_ Complete _ _ _ Complete proﬁles
_ Completers _ _ _ Completers
de jure NCMV Unknown Multiple All subjects All visits
de jure ACMV MAR Multiple All subjects All visits
de jure CCMV Unknown Multiple All subjects All visits
de facto N-BOCF NFD Multiple PCB group All visits
de facto N-LOCF NFD Multiple PCB group All visits
de facto N-DO5 NFD Multiple PCB group All visits
de facto N-AE5 NFD/MAR Multiple PCB group All visits
de facto N-AE5-L NFD/MAR Multiple PCB group Scheduled visits
de facto N-AE10 NFD/MAR Multiple PCB group All visits
de facto N-AE10-L NFD/MAR Multiple PCB group Scheduled visits
de facto N-AE15 NFD/MAR Multiple PCB group All visits
de facto N-AE15-L NFD/MAR Multiple PCB group Scheduled visits
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4 Implementation of PMM analysis using MI
4.1 General features
The PMM analyses are implemented following the standard MI approach, as described in
[11], which includes pattern parameters estimation, missing values imputation, and pooled
analysis. Some other basic features follow general recommendations for MI analysis, which
are stated, justiﬁed, and exempliﬁed in [6]. These are :
1. MI on the original scale followed by analysis of the desired derived outcome is a
more informed strategy than direct analysis of the derived outcome ;
2. Analysis at the desired timepoint provides valid inferences if all the eﬀects are
properly ﬁtted over time by the imputation models ;
3. MI oﬀers a transparent way to represent the impact of drop-out strategies.
In our case study, missing values are imputed on the continuous scale in accordance
with recommendation 1. For the binary outcome, we reuse the data sets imputed on the
continuous scale to derive the clinical responses or non-responses by subject by imputation.
The imputation models used are mixed models for repeated measures (MMRM) with the
three-class factor region and the full baseline-by-visit and group-by-visit interactions for
the ﬁxed eﬀects and unstructured error covariance matrix. The baseline-by-visit interaction
considers possible variation of the impact of baseline over visits. Provided the study is large
enough, such adjustment allows minimum assumption in the imputation stage, so as not to
compromise the analysis stage. To analyze the outcome values at visit 4, we use a covariance
analysis model for the continuous outcome and a logistic regression model for the binary
outcome as originally planned in the trial protocol. Both analysis models incorporate the
pain level at randomization as covariate and the three-class factor region as stratum factor.
According to recommendation 2, these models to analyze outcome values at visit 4 provide
as valid inferences as longitudinal analysis models congenial to the imputation models.
We implement recommendation 3 using summary outcome values by subject which are
directly obtained from the imputed values. The summary continuous values are simply the
means by subject over imputations. For the summary binary values, the clinical responses
or non-responses are derived by subject by imputation. The subject is declared as clinical
responder if at least half of values correspond to clinical responses. The summary values
are used to investigate, via the analysis models described hereabove, the impact of the
drop-out strategies in the subgroups of subjects who dropped out for AE and those who
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dropped out for other reasons. The summary binary values are also used for illustrative
purpose to provide raw frequencies of clinical responders.
Unlike pooled analysis in Rubin's method, an analysis based on summary outcome
ignores between-imputation variance. The relative increase of variance due to missing data
depends on the ratio of the between-imputation variance to the total variance [11]. The
maximum value for this criterion observed across drop-out strategies in our case study was
0.17. This indicates that the magnitude of ignored variance information is moderate. This
also supports the conclusions of subgroup analyses using the summary outcomes.
4.2 Treatment-eﬀect inferences
In this section, we describe a procedure in three stages to estimate the marginal treat-
ment eﬀect in a PMM-MI analysis. It is important to recall that the original Rubin's
method is conditional on patterns by construction. To obtain the marginal eﬀect, the
pattern-speciﬁc eﬀects must be combined into a pattern-average eﬀect. Some aspects of
the procedure are further detailed in [4] and [12]. In the Appendix, we provide information
to implement analysis using a SAS program which combine R functionalities.
4.2.1 Pattern parameter estimation
Distinct models are formulated within each pattern. Let us denote byYi = (yi,1, . . . , yi,T )
the complete outcome vector in the ith subject of pattern t and Yi,obs = (yi,1, . . . , yi,t) its
observed part. The MMRMs per pattern can be expressed as :
Yi,obs = Xiβt + i, (7)
where i ∼N(0,Σt), Σt is unstructured, and the i's are independent. The matrix Xi
contains the known subject covariates whereas βt contains the unknown ﬁxed eﬀects. When
the estimation of parameters is based on the PCB group only, the ﬁxed factor treatment,
and related interactions, are omitted. This ﬁrst stage is aimed at estimating the pattern
parameters βt and Σt. Estimators are denoted by β̂t and Σ̂t in what follows.
4.2.2 Imputation
The process of imputation is conducted sequentially by value. The identifying restriction
indicates from which patterns missing information is borrowed. Whereas imputations under
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CCMV (3) and NCMV (4) use unique patterns, imputations under ACMV (5) and NFMV
(6) are based on several patterns.
We now describe how to obtain a run of M imputed values of yi,t+1 given yi,1, . . . , yi,t.
Multiple imputation of yi,t+2, . . . , yi,T follows the same process by considering the previous
imputed values as observed ones. In our illustration, we suppose that yi,t+1 is imputed
from pattern r (t+1≤r≤T ). Let us denote by µi,r the mean of Yi, which is µi,r = Xiβr.
Based on appropriate parts of µi,r and Σr, we further deﬁne the distributions of Yi,obs ∼
N(µi,r,1,Σr,11) and yi,t+1 ∼ N(µi,r,2,Σr,22). Their covariance terms are denoted by Σr,12
and Σr,21. Using 2|1 as notation for yi,t+1|yi,1, . . . , yi,t, the conditional pattern distribution
of yi,t+1 given yi,1, . . . , yi,t is described by :
fr(yi,t+1|yi,1, . . . , yi,t) ∼ N(µi,r,2|1,Σr,2|1),
where
µi,r,2|1 = µi,r,2 + Σr,21[Σr,11]−1(Yi,obs − µi,r,1),
Σr,2|1 = Σr,22 − Σr,21[Σr,11]−1Σr,12.
(8)
Uncertainty pertaining to the parameters βr and Σr is now incorporated through their
Bayesian distributions. On the basis of the non-informative Jeﬀreys' priors in the Gaussian
context, the values of β̂
(m)
r and Σ̂
(m)
r , m = 1, . . . ,M, are randomly drawn from their
respective posterior predictive distributions. After the derivation of µ̂
(m)
i,r , the imputed
values of yi,t+1 are drawn from the conditional pattern distributions :
f (m)r (yi,t+1|yi,1, . . . , yi,t) ∼ N(µ̂(m)i,r,2|1, Σ̂
(m)
r,2|1), m = 1, . . . ,M. (9)
This stage requires the outcome value at visit 1 to be available. In our case study,
this value is missing in the four subjects of pattern 0, and must be multiply imputed to
begin with. The outcome value at visit 1 is derived from the pain levels at randomization
(covariate) and visit 1. In one subject with missing covariate, the covariate is imputed
from its conditional distribution given the pain level at visit 1 in all subjects. In the three
other subjects of pattern 0 who have missing pain level at visit 1, the missing outcome
value at visit 1 is imputed from its conditional distribution given the covariate in pattern
1 under NCMV, in all subjects under ACMV, and in pattern 5 under CCMV. Next, the
only intermittent missing outcome value after randomization, which occurs in a subject of
pattern 5 at visit 3, is multiply imputed from its conditional distribution given the observed
outcome values in pattern 5.
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4.2.3 Pooled analysis
Direct pooled analysis combines the treatment-eﬀect estimates d̂(m) obtained in impu-
tations m, m = 1, ...,M . According to Rubin's rule [11], the pooled estimate d is the mean
of d̂(m) and the pooled variance is given by :
V = W +
(
M + 1
M
)
B, (10)
where W is the mean of d(m)'s variances and B is the between-imputation variance such
that :
B =
1
M − 1
M∑
m=1
(d̂(m) − d)2.
To test the hypothesis of no treatment eﬀect, the statistic d/
√
V approximately follows a
t-Student distribution with degrees-of-freedom equal to r = (M −1)[1 +W/(1 +M−1)B]2.
Direct pooled analysis provides consistent treatment-eﬀect estimate. However, inferences
are conditional on pattern probabilities by construction. This conditioning is inappropriate
in our context of a conﬁrmatory clinical trial wherein inferences on marginal eﬀects are
expected.
For this purpose, we average the treatment eﬀects across patterns with respect to pattern
probabilities. Let us introduce the MT -dimensional vector :
d = (dˆ
(1)
1 , . . . , dˆ
(M)
1 , . . . , dˆ
(1)
T , . . . , dˆ
(M)
T ),
where dˆ
(m)
t is the estimate in pattern t and imputation m. Using Rubin's rule, we ﬁrst
derive the vector of pooled estimates per pattern which is denoted by d∗=(d∗1,. . .,d∗T ) in
what follows. So, the d∗t 's are the means of the dˆ
(m)
t 's per pattern and V
∗ is the T ×T -
dimensional total covariance matrix of d∗ which is given by :
V ∗ = W ∗ +
(
M + 1
M
)
B∗,
whereW ∗ is the diagonal matrix whose coeﬃcients are the means of the d∗t 's variances and
B∗ is the correlation matrix of d∗.
Then, the pattern-speciﬁc information is combined with respect to the multinomial
distribution of patterns. To this end, we use Rubin's rule a second time to derive the
pattern-average parameters which are denoted by d†, W †, and B†, respectively, in what
follows. Let us deﬁne the vector Π that contains the pattern probabilities, the marginal
treatment eﬀect is given by :
d† = Π′d∗. (11)
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The total variance takes the form :
V † = W † +
(
T + 1
T
)
B†, (12)
where W †=Π′W ∗Π+d∗
′
Var(Π)d∗ and B†=Π′B∗Π. These formulas were derived and jus-
tiﬁed in [12]. To test the hypothesis of no treatment eﬀect, the statistic d†/
√
V † approxi-
mately follows a t-Student distribution with a degrees-of-freedom equal to (T − 1) ∗ {1 +
W †/[(1 + T−1) ∗B†)]2}.
As mentioned in [13], it is important to recall that averaging regression coeﬃcients (such
as treatment eﬀect) over pattern assumes that covariates (such as treatment assignment)
are equally distributed across patterns, otherwise estimators are biased. In other words, (11)
assumes homogenous pattern probabilities in the two treatment groups. This assumption
is questionable in our case study. Figure 1 indicates that the pattern probabilities are
Π̂
′
P = (.065, .047, .027, .029, .831) for PCB and Π̂
′
T = (.141, .063, .039, .044, .712) for Test
and the classical χ2 to test homogeneity between treatment groups yields p<0.01.
To tackle this issue, we introduce the idea of replacing d† in the test of the marginal
eﬀect by d the point estimate of the pattern-conditional eﬀect. Although this approach
may appear somewhat inelegant as the statistic d/
√
V † is based on two terms given by dif-
ferent methods, it oﬀers a pragmatic solution in presence of moderate imbalance in pattern
probabilities between treatment groups. The justiﬁcation rests upon the two main goals
of analysis. The ﬁrst is to provide unbiased point estimate. However, d is consistent. The
second is to draw inferences without type 1 error inﬂation. Under homogeneity assumption,
the test of the marginal eﬀect is more conservative than the test of the pattern-conditional
eﬀect as the integration of the distribution of patterns increases the variance V † in (12)
relative to V in (10). Thus, our approach merely consists of using the appropriate terms to
fulﬁll the two conditions given above. To unambiguously identify it in what follows, this
approach is named corrected marginal approach.
All the results shown in the next section are obtained from the corrected marginal
approach. To allow comprehensive interpretation, we also provide the results based on
the full analyses of the pattern-conditional and the marginal eﬀects in Section 5.3. This
analysis scheme can be seen as a small, perhaps informal, attempt to formalize a set of
primary and sensitivity analyses.
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5 Results
5.1 Continuous outcome analysis
Figure 2 displays treatment-eﬀect estimates obtained with the continuous outcome at
visit 4 under the drop-out strategies speciﬁed in Table 3. We provide the diﬀerences between
treatment groups with their 95% conﬁdence limits and p-values. Results by treatment group
are expressed in terms of adjusted means with standard errors.
As expected, owing to the greater drop-out rate in the Test group, the treatment eﬀect
estimated after LOCF imputation [4.30 (1.41) p=0.002] lies between that obtained after
BOCF imputation [2.85 (1.37) p=0.038] and in subjects with complete outcome [5.87 (1.61)
p<.0001]. Relative to BOCF, LOCF increases the means by treatment group by 0.1 for PCB
and 1.6 for Test, suggesting that drop-out subjects under Test beneﬁt from the treatment.
Next, the treatment eﬀect estimated in completers [5.14 (1.66) p=0.002] is lower than that
obtained in subjects with complete outcome. This result was expected since subjects with
complete outcome consist of the subjects of pattern 4 and the completers, and Figure 1
exhibits a huge diﬀerence between treatment groups in pattern 4.
Among PMM analyses, the results of de jure analyses exhibit weak variations. As ex-
pected, CCMV which uses the pattern of completers for imputation produces larger means
by treatment group (11.9 for PCB and 16.9 for Test) than ACMV which uses all patterns
(11.7 for PCB and 16.4 for Test) and NCMV which uses the closest neighboring patterns
(10.7 for PCB and 15.6 for Test). CCMV also produces a larger treatment eﬀect [5.03
(1.63) p=0.002] than ACMV [4.78 (1.63) p=0.004] and NCMV [4.85 (1.67) p=0.004].
The de facto analyses exhibit greater divergences. The treatment eﬀect estimated under
N-LOCF [3.92 (1.72) p=0.024] is related to that obtained with the single-imputation coun-
terpart LOCF whereas N-BOCF [1.52 (1.89) p=0.424] provides a lower estimate than that
obtained with BOCF. The allowance for appropriate uncertainty in the NFD strategies
increases standard errors and p-values. Unlike BOCF, the treatment eﬀect under N-BOCF
is not statistically signiﬁcant.
Owing to the greater drop-out rate in the Test group, the penalty for drop-out ∆ =
−5 decreases by 0.71 the treatment eﬀect estimated under N-DO5 [3.21 (1.78) p=0.073]
relative to N-LOCF which involves ∆ = 0. The inferences produced by N-AE5 [3.13 (1.74)
p=0.0073] are very close to those of N-DO5 although the penalty is zeroed if subjects
dropped out for other reasons than AE. Indeed, these subjects are similarly distributed in
the two groups (7.4% for PCB and 7.0% for Test based on Table 1) so that the means by
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Figure 2  Treatment-eﬀect estimates obtained with the continuous outcome at visit 4.
treatment group estimated under N-AE5 increase similarly (+0.6 for PCB and +0.5 for
Test). As a global rule for the N-AEx strategies, the penalty increase makes the treatment-
eﬀect estimate decreasing, as observed under N-AE10 [2.21 (1.80) p=0.222] and N-AE15
[1.23 (1.90) p=0.520].
For the N-AEx-L strategies, the removal of the last visit if drop-out is caused by an AE
increases the means by treatment group relative to the N-AEx counterparts. This impact
was expected since Figure 1 exhibits mean proﬁles in the drop-out patterns which slightly
decline at the last visit. The removal of the last visit also increases the separation between
treatment groups under N-AE5-L [3.58 (1.73) p=0.040], N-AE10-L [2.82 (1.76) p=0.111],
and N-AE15-L [2.04 (1.80) p=0.259].
Several authors have suggested the search of a penalty value applicable to drop-out
subjects at which conclusions change from being favorable for Test to being unfavorable
[14]. In our case study, we have conducted such investigation under the strategies N-AEx
and N-AEx-L. The limit values which zero the treatment eﬀect (i.e., no diﬀerence between
treatment groups) are ∆ = −21 under N-AEx and ∆ = −30 under N-AEx-L. In the same
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vein, the limit values which cancel the statistical signiﬁcance (i.e., p=0.05) are ∆ = −3
under N-AEx and ∆ = −6 under N-AEx-L. These limit values can be interpreted as the
maximum price to pay for drop-out so that Test remains beneﬁcial to subjects in the trial.
If the penalty value is below these limit values, the risks for subjects do not balance the
beneﬁts of Test. Of note, several authors have also suggested to introduce conservatism,
such as in the δ-method [15], by deliberately penalizing subjects of the Test group. In our
analysis, the penalties are applied to drop-out subjects whatever their treatment groups.
Ultimately, this allows a sensible representation of true treatment eﬀects, underpinning a
main trial objective [16].
5.2 Binary outcome analysis
Figure 3 displays treatment-eﬀect estimates obtained with the binary outcome at visit
4 under the drop-out strategies speciﬁed in Table 3. We provide odds-ratios with their 95%
conﬁdence limits and p-values. Results by treatment group are described with frequencies
and percentages of clinical responders based on the summary binary values.
The inferences obtained after BOCF [1.37 (0.15) p=0.029] and LOCF [1.53 (0.14)
p=0.003] imputations conﬁrm the major trends observed with the continuous outcome.
The greater odds-ratio value obtained after LOCF imputation relative to BOCF is cau-
sed by 16 additional clinical responders for Test against 5 for PCB. Despite the change
of outcome scale, the p-values obtained after BOCF and LOCF imputations, as well as
in subjects with complete outcome [1.74 (0.16) p<0.001] and in completers [1.63 (0.16)
p=0.002], are surprisingly identical to those obtained with the continuous outcome.
The de jure analyses now exhibit a moderate divergence between CCMV [1.63 (0.18)
p=0.006], ACMV [1.58 (0.18) p=0.011], and NCMV [1.46 (0.20) p=0.061]. Particularly,
the treatment eﬀect estimated under NCMV is not statistically signiﬁcant. Among de
facto analyses, the treatment eﬀect estimated under N-LOCF [1.52 (0.19) p=0.027] is still
greater than that estimated under N-BOCF [1.39 (0.21) p=0.117]. The diﬀerence is caused
by 13 additional clinical responders for Test against 3 for PCB. As with the continuous
outcome, N-DO5 [1.48 (0.21) p=0.059] and N-AE5 [1.47 (0.19) p=0.047] provide similar
treatment-eﬀect estimates although only N-AE5 is statistically signiﬁcant.
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Figure 3  Treatment-eﬀect estimates obtained with the binary outcome at visit 4.
Whereas inferences obtained so far with the binary outcome remain coherent with the
continuous case, the N-AEx strategies exhibit divergences. The penalty increase only im-
plies a slight decrease of odds-ratios as observed under N-AE10 [1.45 (0.20) p=0.070] and
N-AE15 [1.43 (0.21) p=0.090] relative to N-AE5, although the p-values change to statis-
tically non-signiﬁcant. The slight impact on odds-ratios is caused by a ﬂoor eﬀect on the
numbers of clinical responders. From N-AE5 to N-AE15, these numbers vary from 134 to
133 for PCB and from 163 to 162 for Test. A similar impact of penalty increase is observed
in N-AE5-L [1.50 (0.19) p=0.033], N-AE10-L [1.45 (0.20) p=0.059], and N-AE15-L [1.42
(0.21) p=0.097]. Another consequence of the ﬂoor eﬀect is that the treatment eﬀect under
the N-AEx and the N-AEx-L strategies remains in favor of Test (i.e., odds-ratio>1) wha-
tever the ∆ value. Otherwise, the limit values for statistical non-signiﬁcance are ∆ = −6
under N-AEx and ∆ = −8 under N-AEx-L.
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5.3 Sensitivity analysis
Table 4 compares the results obtained from the corrected marginal approach which are
laid out in Figure 2 and Figure 3 with those based on full analyses of the pattern-conditional
and the marginal eﬀects.
Table 4  Results obtained from the corrected marginal approach and based on full analyses of
the pattern-conditional and the marginal eﬀects.
Outcome Drop-out pattern-conditional Corrected marginal Marginal
strategies eﬀect approach eﬀect
CONTINUOUS CCMV 5.03 (1.50) 0.001 5.03 (1.63) 0.002 5.15 (1.63) 0.002
Diﬀerence (s.e.) p ACMV 4.78 (1.49) 0.001 4.78 (1.63) 0.004 4.94 (1.63) 0.003
NCMV 4.85 (1.51) 0.001 4.85 (1.67) 0.004 5.05 (1.67) 0.003
N-BOCF 1.52 (1.79) 0.397 1.52 (1.89) 0.424 1.83 (1.89) 0.272
N-LOCF 3.92 (1.59) 0.014 3.92 (1.72) 0.024 4.04 (1.72) 0.020
N-DO5 3.21 (1.67) 0.055 3.21 (1.78) 0.073 3.31 (1.78) 0.064
N-AE5 3.13 (1.63) 0.055 3.13 (1.74) 0.073 3.30 (1.74) 0.059
N-AE10 2.21 (1.71) 0.198 2.21 (1.80) 0.222 2.38 (1.80) 0.187
N-AE15 1.23 (1.83) 0.503 1.23 (1.90) 0.520 1.42 (1.90) 0.458
N-AE5-L 3.58 (1.58) 0.023 3.58 (1.73) 0.040 3.85 (1.73) 0.027
N-AE10-L 2.82 (1.62) 0.082 2.82 (1.76) 0.111 3.06 (1.76) 0.084
N-AE15-L 2.04 (1.68) 0.223 2.04 (1.80) 0.259 2.25 (1.80) 0.213
BINARY CCMV 1.63 (0.15) 0.001 1.63 (0.18) 0.006 1.62 (0.18) 0.007
Odds-Ratio (s.e.) p ACMV 1.58 (0.15) 0.002 1.58 (0.18) 0.011 1.57 (0.18) 0.013
NCMV 1.46 (0.15) 0.010 1.46 (0.20) 0.061 1.42 (0.20) 0.084
N-BOCF 1.39 (0.15) 0.028 1.39 (0.21) 0.117 1.26 (0.21) 0.272
N-LOCF 1.52 (0.15) 0.005 1.52 (0.19) 0.027 1.47 (0.19) 0.039
N-DO5 1.48 (0.15) 0.008 1.48 (0.21) 0.059 1.42 (0.21) 0.089
N-AE5 1.47 (0.15) 0.009 1.47 (0.19) 0.047 1.42 (0.19) 0.071
N-AE10 1.45 (0.15) 0.013 1.45 (0.20) 0.070 1.37 (0.20) 0.114
N-AE15 1.43 (0.15) 0.017 1.43 (0.21) 0.090 1.34 (0.21) 0.159
N-AE5-L 1.50 (0.15) 0.007 1.50 (0.19) 0.033 1.51 (0.19) 0.031
N-AE10-L 1.45 (0.15) 0.012 1.45 (0.20) 0.059 1.44 (0.20) 0.064
N-AE15-L 1.42 (0.15) 0.020 1.42 (0.21) 0.097 1.39 (0.21) 0.115
For the continuous outcome, an overall look at results across strategies indicates that
the point estimates based on the marginal eﬀect are always greater than those given by
the pattern-conditional eﬀect. This is a consequence of the imbalance in the treatment
assignment across patterns. The over-estimation by the marginal eﬀect is moderate with
a variation from 0.10 under N-DO5 to 0.31 under N-BOCF. The marginal eﬀect also
produces greater standard errors because of the integration of the distribution of pat-
terns. Consequently, the corrected marginal approach, which combines terms given by the
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pattern-conditional and the marginal eﬀects, yields the most conservative inferences. Of
note, the inferences remain coherent across approaches since none of the p-values switches
from signiﬁcant to non-signiﬁcant, and vice-et-versa, from one approach to the other.
The coherence across approaches observed on the continuous outcome does not hold
on the binary scale because of the non-linear metric used to characterize treatment-eﬀect
magnitude. Except in N-AE5-L, the point estimates of the marginal eﬀect are now lower
than those of the conditional-pattern eﬀect. Of the twelve strategies, height exhibit discre-
pancies in inferences between the pattern-conditional and the marginal eﬀects. However,
the inferences obtained from the corrected marginal approach and marginal eﬀect analysis
are almost coherent since only N-AE5 exhibits a discrepancy with 1.47 (0.19) p=0.047 for
the ﬁrst and 1.42 (0.19) p=0.071 for the second.
5.4 Subgroup analysis
Table 5 provides the treatment-eﬀect estimates in the subgroups of subjects who drop-
ped out for AE (DOAE) and other reasons than AE (DOnotAE).
In the subgroup DOAE, only NCMV on the continuous scale yields a statistically si-
gniﬁcant eﬀect of Test. The other drop-out strategies produce treatment eﬀects that are
either clinically moderate or counterbalanced by the penalties for drop-out in the N-AEx
and N-AEx-L strategies. The subgroup DOnotAE exhibits opposite results since all the
drop-out strategies, except N-BOCF on the continuous scale, yield statistically signiﬁcant
eﬀects of Test. In this subgroup, the continuous outcome means by treatment group are all
positive for Test and negative for PCB, whereas the rates of clinical responders are always
greater in the Test group.
These results show no evidence of treatment eﬀect in the subjects who dropped out
for AE whereas the subjects who dropped out for other reasons unambiguously beneﬁted
from Test. The lack of treatment eﬀect in subjects suﬀering from AE indicates that subjects
actually suﬀered from inconveniences inﬂuencing there VAS score which were not relievable
by a treatment indicated to the targeted disease (i.e., ﬁbromyalgia). This also underlines
the relevance of the N-AEx-L strategies in our case study.
Further attention is needed to interpret the results after BOCF imputation. They exhi-
bit non-null continuous outcome means by treatment group and some clinical responders
although BOCF assigns a 0 value and a non-clinical response. In fact, these outcome values
come from the subjects of pattern 4 who dropped out after visit 3 and had their drop-out
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Table 5  Treatment-eﬀect estimates in the subgroups of subjects who dropped out for AE and
other reasons than AE († indicates a treatment eﬀect in favor of PCB).
Subgroups Drop-out Mean Diﬀ (se) p Freq (%) OR (se) p
strategies PCB Test PCB Test
DOAE BOCF -.10 2.2 2.3 (1.4) 0.098 0/44 (0.0) 4/96 (4.2) 5.23 (1.37) 0.228
LOCF 5.0 7.6 2.6 (2.9) 0.372 5/44 (11.4) 18/96 (18.7) 1.9 (0.56) 0.257
CCMV 9.1 13.2 4.0 (2.7) 0.130 7/44 (15.9) 26/96 (27.1) 1.74 (0.47) 0.234
ACMV 7.9 11.4 3.5 (2.5) 0.172 7/44 (15.9) 24/96 (25.0) 1.57 (0.47) 0.335
NCMV .45 8.5 8.1 (2.1) <.001 5/44 (11.4) 10/96 (10.4) 0.85 (0.56) 0.768 †
N-BOCF -1.4 -2.4 -1.0 (2.8) 0.722 3/44 (6.8) 4/96 (4.2) 0.59 (0.72) 0.460 †
N-LOCF 3.4 6.2 2.8 (2.7) 0.308 6/44 (13.6) 15/96 (15.6) 1.10 (0.51) 0.854
N-DO5 -1.9 .36 2.3 (2.8) 0.418 5/44 (11.4) 12/96 (12.5) 1.02 (0.55) 0.966
N-AE5 -.64 .62 1.3 (2.9) 0.667 5/44 (11.4) 12/96 (12.5) 1.02 (0.55) 0.966
N-AE10 -4.9 -5.3 -.38 (3.2) 0.907 † 5/44 (11.4) 11/96 (11.5) 0.93 (0.55) 0.903 †
N-AE15 -9.6 -12.0 -2.1 (3.7) 0.576 † 4/44 (9.1) 11/96 (11.5) 1.19 (0.59) 0.770
N-AE5-L 5.7 5.2 -.47 (2.1) 0.822 † 5/44 (11.4) 13/96 (13.5) 1.07 (0.54) 0.902
N-AE10-L 1.8 .07 -1.7 (2.2) 0.431 † 4/44 (9.1) 8/96 (8.3) 0.83 (0.61) 0.755 †
N-AE15-L -2.2 -5.1 -2.9 (2.3) 0.206 † 4/44 (9.1) 6/96 (6.3) 0.63 (0.63) 0.467 †
DOnotAE BOCF -1.0 6.7 7.7 (2.7) 0.006 1/33 (3.0) 7/30 (23.3) 9.0 (0.95) 0.021
LOCF -5.7 12.3 18.1 (3.6) <.001 1/33 (3.0) 9/30 (30.0) 17.7 (1.02) 0.005
CCMV -2.2 15.8 18.0 (2.6) <.001 2/33 (6.0) 11/30 (36.7) 8.71 (0.78) 0.006
ACMV -3.3 14.8 18.1 (3.3) <.001 2/33 (6.0) 11/30 (36.7) 8.71 (0.78) 0.006
NCMV -5.8 12.0 17.8 (2.3) <.001 1/33 (3.0) 9/30 (30.0) 12.7 (0.96) 0.008
N-BOCF -.89 .54 1.43 (4.4) 0.747 1/33 (3.0) 7/30 (23.3) 7.10 (0.92) 0.034
N-LOCF -5.1 11.1 16.2 (3.5) <.001 1/33 (3.0) 9/30 (30.0) 12.7 (0.96) 0.008
N-DO5 -9.5 7.25 16.7 (3.7) <.001 1/33 (3.0) 9/30 (30.0) 12.7 (0.96) 0.008
N-AEx -3.3 14.3 17.7 (3.5) <.001 2/33 (6.0) 10/30 (33.3) 7.62 (0.79) 0.010
N-AEx-L -2.8 14.6 17.4 (3.5) <.001 2/33 (6.0) 10/30 (33.3) 7.62 (0.79) 0.010
visit repositioned to visit 4 for analysis.
The results obtained under NCMV in the subgroup DOAE also deserve explanations
since the eﬀect of Test is statistically signiﬁcant with the continuous outcome [8.1 (2.1)
p<.001] whereas analysis on the binary scale yields a slight advantage in favor of PCB
[OR=0.85 (0.56) p=0.768]. Relative to CCMV, the means by treatment group under NCMV
decrease by -8.6 for PCB and -4.7 for Test. Such impact was expected from Figure 1, which
exhibits a marked divergence in the mean proﬁles between the drop-out patterns 14 used
in NCMV and pattern 5 of completers used in CCMV. In parallel, the numbers of clinical
responders decrease by −2/44 (−4.5%) for PCB and −15/96 (−15.6%) for Test. These
contradictory results between the continuous and the binary outcomes are only caused by
a scale eﬀect. The substantial gain for PCB on the continuous scale corresponds to few
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additional clinical responders because the threshold of 30% improvement is not reached.
These results in the subgroup DOAE explain the divergence between the inferences under
NCMV based on the continuous and the binary outcomes in the whole sample.
Under the N-AEx and N-AEx-L strategies, the inﬂuence of the penalty for drop-out
in the subgroup DOAE is unsurprisingly quasi-linear on the continuous scale. Conversely,
the impact on the binary outcome is weak because of the ﬂoor eﬀect. In the subgroup
DOnotAE, the penalty has no impact at all since subjects are imputed assuming MAR.
6 Discussion
Planning a PMM-MI analysis requires one to question and address all the aspects of
implementation. In our case study, MMRMs with full interaction of treatment by visit are
used for imputation. This modeling strategy has driven the deﬁnition of patterns, which are
based on drop-out at each visit. In this context, the large number of parameters required
and the sharing of parameters often emerge as a limiting factor as the pattern sizes do not
allow to accommodate all the potentially useful information. Although the same pattern is
supposed to represent the same kind of subjects, it is likely that the correlation structure
in subjects who dropped out for AEs diﬀers from that of subjects who dropped out for
other reasons. Furthermore, while we estimate parameters separately for each pattern, we
also assumed, in de jure analyses, that the covariance is the same across treatment groups.
Another important aspect of our implementation concerns the derivation of the condi-
tional pattern distributions in (8). The method is based on J2R which is implemented by
default in our software solution. After drop-out, patient's mean response distribution is
now that of the PCB group. Such a change may be seen as a worst-case scenario in terms
of reducing any treatment eﬀect since drop-out subjects on Test will lose the eﬀect of
their period on treatment. With additional programming, J2R can be replaced by another
method such as copy increments in reference [17]. This alternative performs imputation
so that the subject's mean proﬁle tracks that of the mean proﬁle in the PCB group, but
starting from the beneﬁt already obtained with Test if a given subject was on Test before
drop-out.
Planning a PMM-MI analysis also requires one to cautiously examine characteristics of
patterns like the pattern sizes (e.g., majority completer versus spread over many patterns)
and the proximity between patterns (e.g., are there major jumps in mean and/or variance
structure from one pattern to the neighboring one). Imputation based on the pattern
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of completers may contribute to undue overestimation of the treatment eﬀect and may
impose inappropriately low uncertainty. In our case study, imputation is based on the
drop-out patterns only. These patterns have homogeneous sizes and their mean proﬁles
exhibit stable trends over time. The consequence is that, outside the eﬀect of the free
distribution of values present under NFD, drop-out strategies have a moderate impact on
treatment-eﬀect estimates, while a reasonable amount of uncertainty is allowed. It is also
important to note that, under NFD, early drop-out has less impact, compared to MAR,
than late drop-out assuming commonly used covariance structures. It is a concept that
several statisticians may ﬁnd counter-intuitive when reﬂecting upon de facto analysis.
In our NFD implementation, the present corresponds to the ﬁrst unobserved visit and
the distribution of present values are deﬁned relative to the drop-out visits in the closest
neighboring patterns. It is important to assess the impact of these choices, especially as we
cannot rule out that eﬃcacy assessments at these visits combine other aspects related to
tolerance. In our case study, we considered that including the drop-out visits in the analysis
does not bias eﬃcacy evaluation and, on the contrary, provides valuable information for
treatment-eﬀect estimation. This statement is based on the comparisons of analysis results
with and without the drop-out visits, wherein the moderate diﬀerence observed was in line
with what was observed in the mean proﬁles of patterns.
7 Concluding remarks
As already stated and exempliﬁed in [17], PMM-MI methods permit the implementation
of various assumptions on missingness mechanisms. Among them, NFD oﬀers an appealing
setting to formalize beliefs on drop-out and address a large spectrum of scientiﬁc issues.
Strategies can easily be tailored according to plausible clinical scenarios. We show that
NFD oﬀers powerful solutions to tackle major drawbacks of well-known single-imputation
concepts such as BOCF and LOCF. We also show that strategies may aim to balance the
beneﬁts against risks in the assessment of the treatment eﬀect. Of note, in our case study
it was very feasible to reﬁne the penalties for drop-out by incorporating some information
on the type of adverse event leading to drop-out as given in Section 2.2. So, the penalties
are adjusted according to the impact of AE on the subject. An important aspect of our
NFD-PMM-MI approach is that it aims more at analysing an outcome whose value is
corrected in some circumstances related to drop-out, rather than directly challenging the
statistical properties of a primary analysis. As such, the approach ﬁts more into the concept
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of estimand than the ﬁeld of sensitivity analysis.
The possibility to draw inferences on the marginal treatment eﬀect is an important as-
pect of our implementation. This characteristic is compatible with analyses of conﬁrmatory
RCTs. In this setting, we point to the issue of imbalance in the treatment allocations across
patterns very clearly and we suggest a pragmatic way out in the presence of moderate im-
balance. These cases of imbalance are common in PCB-controlled trials in chronic pain
when the test treatment causes early drop-out due to adverse reactions. Another possibi-
lity allowed by MI-based methods is the investigation of the impact of drop-out strategies
in subgroups of interest using the individual proﬁles averaged over imputation.
Any candidate method to analyse conﬁrmatory RCTs implies the possibility to plan all
the aspects of analysis before breaking the blind. In this manuscript, we highlight several
points to consider that can be addressed during analysis preparation. We also show how
to implement the approach using a freely available existing program. Accordingly, there
is now no reason not to consider an NFD assumption and PMM-MI methods for primary
and sensitivity analyses in conﬁrmatory RCTs.
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Appendix : Software implementation
This appendix provides the reader with additional information to implement the
corrected marginal approach using an existing SAS program which combines R func-
tionalities [4]. This program produces pooled treatment-eﬀect estimates under NCMV,
ACMV, NCMV, and NFMV using the three-stage Rubin's method. Minimal know-
ledges in SAS and R are needed to implement the additional functionalities.
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In the existing program, estimation of parameters and pooled analysis are perfor-
med in SAS whereas MI is entirely carried out under R. The program structure of the
R script is a ﬁrst limitation as MI is conducted under the same identifying restrictions
in all subjects. The reason is that MI speciﬁcations, including the identifying restric-
tion, are entered once in the SAS program and are then exported to R. To allow for
individual imputation schemes, the loop for subject imputation must be transfered
from the R script into the SAS program. Of note, this causes much more calls of R
from SAS when running the program.
Next, the existing program does not impute missing covariates and ﬁrst outcome
values. This functionality must be inserted in the R script using a syntax similar to
that used for imputation of the other missing values. Another modiﬁcation in the
R script concerns the numbering of patterns and the number of observed visits per
pattern which match by default. In our case study, subjects with complete outcome
proﬁle may pertain to patterns 4 or pattern 5 although four visits are observed in
subjects of both patterns. Information on how to decouple these two parameters is
available in Section 7.4 in [4].
To end, the syntax to perform the direct pooled analysis in the SAS program must
be replaced by a syntax to perform pooled analyses per pattern and then average
treatment eﬀects accross patterns. Using the notation in Section 4.2.3, we suggest the
following algorithm :
1. Use SAS Proc MIXED or SAS Proc LOGISTIC to ﬁt outcome values at visit 4
per pattern by imputation and estimate d and standard errors ;
2. Use SAS Proc FREQ to estimate the pattern probabilities in Π ;
3. Use SAS Proc MIANALYZE to estimate d∗ and W ∗ which contain pooled treat-
ment eﬀects and within-imputation standard errors per pattern ;
4. Use SAS Proc CORR to estimate the between-imputation covariance matrix B∗ ;
5. Use R or SAS to calculate the pattern-averaged parameters W †, B†, V † and pro-
duce the results.
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